blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3471727

EP3471727 - CXCR4 INHIBITORS AND USES THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  18.10.2021
Database last updated on 11.09.2024
FormerThe patent has been granted
Status updated on  06.11.2020
FormerGrant of patent is intended
Status updated on  23.06.2020
FormerRequest for examination was made
Status updated on  22.03.2019
FormerThe international publication has been made
Status updated on  29.12.2017
Most recent event   Tooltip14.06.2024Lapse of the patent in a contracting state
New state(s): TR		published on 17.07.2024  [2024/29]
Applicant(s)For all designated states
X4 Pharmaceuticals, Inc.
955 Massachusetts Avenue 4th Floor
Cambridge, Massachusetts 02139 / US
[2019/17]
Inventor(s)01 / BOURQUE, Elyse Marie Josee
162 Ch Bouffard
L'Etang-du-Nord, Quebec G4T 3G6 / CA
02 / SKERLJ, Renato
12 Crocker Circle
West Newton, Massachusetts 02465 / US
 [2019/26]
Former [2019/17]01 / BOURQUE, Elyse Marie Josee
3115 Racine Street
Unit 214
Bellingham, Washington 98226 / US
02 / SKERLJ, Renato
12 Crocker Circle
West Newton, Massachusetts 02465 / US
Representative(s)Tostmann, Holger Carl
Wallinger Ricker Schlotter Tostmann
Patent- und Rechtsanwälte Partnerschaft mbB
Zweibrückenstrasse 5-7
80331 München / DE
[2019/17]
Application number, filing date17816163.421.06.2017
[2019/17]
WO2017US38609
Priority number, dateUS201662352820P21.06.2016         Original published format: US 201662352820 P
US201762456526P08.02.2017         Original published format: US 201762456526 P
[2019/17]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017223239
Date:28.12.2017
Language:EN
[2017/52]
Type: A1 Application with search report 
No.:EP3471727
Date:24.04.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 28.12.2017 takes the place of the publication of the European patent application.
[2019/17]
Type: B1 Patent specification 
No.:EP3471727
Date:09.12.2020
Language:EN
[2020/50]
Search report(s)International search report - published on:US28.12.2017
(Supplementary) European search report - dispatched on:EP06.09.2019
ClassificationIPC:A61K31/445, A61K31/437, C07D471/04, A61P35/00
[2019/41]
CPC:
A61P35/00 (EP,CN,US); C07D471/04 (EP,CN,US); C07D519/00 (US)
Former IPC [2019/17]A61K31/445, A61K31/437, C07D471/04
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/17]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:CXCR4-INHIBITOREN UND VERWENDUNGEN DAVON[2019/17]
English:CXCR4 INHIBITORS AND USES THEREOF[2019/17]
French:INHIBITEURS DE CXCR4 ET LEURS UTILISATIONS[2019/17]
Entry into regional phase13.12.2018National basic fee paid 
13.12.2018Search fee paid 
13.12.2018Designation fee(s) paid 
13.12.2018Examination fee paid 
Examination proceduredeletedDate on which the examining division has become responsible
13.12.2018Examination requested  [2019/17]
03.04.2020Amendment by applicant (claims and/or description)
24.06.2020Communication of intention to grant the patent
02.11.2020Fee for grant paid
02.11.2020Fee for publishing/printing paid
02.11.2020Receipt of the translation of the claim(s)
Divisional application(s)EP20212271.9  / EP3808748
Opposition(s)10.09.2021No opposition filed within time limit [2021/46]
Fees paidRenewal fee
27.06.2019Renewal fee patent year 03
29.06.2020Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU21.06.2017
AL09.12.2020
AT09.12.2020
CY09.12.2020
CZ09.12.2020
DK09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
MC09.12.2020
MK09.12.2020
PL09.12.2020
RO09.12.2020
RS09.12.2020
SI09.12.2020
SK09.12.2020
SM09.12.2020
TR09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
IS09.04.2021
PT09.04.2021
LU21.06.2021
[2024/29]
Former [2024/23]HU21.06.2017
AL09.12.2020
AT09.12.2020
CY09.12.2020
CZ09.12.2020
DK09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
MC09.12.2020
MK09.12.2020
PL09.12.2020
RO09.12.2020
RS09.12.2020
SI09.12.2020
SK09.12.2020
SM09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
IS09.04.2021
PT09.04.2021
LU21.06.2021
Former [2023/33]HU21.06.2017
AL09.12.2020
AT09.12.2020
CY09.12.2020
CZ09.12.2020
DK09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
MC09.12.2020
PL09.12.2020
RO09.12.2020
RS09.12.2020
SI09.12.2020
SK09.12.2020
SM09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
IS09.04.2021
PT09.04.2021
LU21.06.2021
Former [2023/30]AL09.12.2020
AT09.12.2020
CY09.12.2020
CZ09.12.2020
DK09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
MC09.12.2020
PL09.12.2020
RO09.12.2020
RS09.12.2020
SI09.12.2020
SK09.12.2020
SM09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
IS09.04.2021
PT09.04.2021
LU21.06.2021
Former [2022/23]AL09.12.2020
AT09.12.2020
CZ09.12.2020
DK09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
MC09.12.2020
PL09.12.2020
RO09.12.2020
RS09.12.2020
SI09.12.2020
SK09.12.2020
SM09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
IS09.04.2021
PT09.04.2021
LU21.06.2021
Former [2022/18]AL09.12.2020
AT09.12.2020
CZ09.12.2020
DK09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
MC09.12.2020
PL09.12.2020
RO09.12.2020
RS09.12.2020
SI09.12.2020
SK09.12.2020
SM09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
PT09.04.2021
LU21.06.2021
Former [2022/10]AL09.12.2020
AT09.12.2020
CZ09.12.2020
DK09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
MC09.12.2020
PL09.12.2020
RO09.12.2020
RS09.12.2020
SI09.12.2020
SK09.12.2020
SM09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
PT09.04.2021
Former [2022/08]AL09.12.2020
AT09.12.2020
CZ09.12.2020
DK09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
MC09.12.2020
PL09.12.2020
RO09.12.2020
RS09.12.2020
SI09.12.2020
SK09.12.2020
SM09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
IS09.04.2021
PT09.04.2021
Former [2021/49]AL09.12.2020
AT09.12.2020
CZ09.12.2020
DK09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
PL09.12.2020
RO09.12.2020
RS09.12.2020
SI09.12.2020
SK09.12.2020
SM09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
IS09.04.2021
PT09.04.2021
Former [2021/45]AL09.12.2020
AT09.12.2020
CZ09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
PL09.12.2020
RO09.12.2020
RS09.12.2020
SK09.12.2020
SM09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
IS09.04.2021
PT09.04.2021
Former [2021/42]AT09.12.2020
CZ09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
PL09.12.2020
RO09.12.2020
RS09.12.2020
SK09.12.2020
SM09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
IS09.04.2021
PT09.04.2021
Former [2021/39]AT09.12.2020
CZ09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
PL09.12.2020
RO09.12.2020
RS09.12.2020
SK09.12.2020
SM09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
PT09.04.2021
Former [2021/37]AT09.12.2020
CZ09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
RO09.12.2020
RS09.12.2020
SK09.12.2020
SM09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
PT09.04.2021
Former [2021/36]CZ09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
RO09.12.2020
RS09.12.2020
SK09.12.2020
SM09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
PT09.04.2021
Former [2021/35]CZ09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
RO09.12.2020
RS09.12.2020
SK09.12.2020
SM09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
PT09.04.2021
Former [2021/33]FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
RS09.12.2020
SM09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
PT09.04.2021
Former [2021/32]FI09.12.2020
HR09.12.2020
LV09.12.2020
RS09.12.2020
SM09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
Former [2021/28]FI09.12.2020
HR09.12.2020
LV09.12.2020
RS09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
Former [2021/23]FI09.12.2020
LV09.12.2020
RS09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
Former [2021/22]FI09.12.2020
RS09.12.2020
NO09.03.2021
Former [2021/20]FI09.12.2020
Documents cited:Search[A]WO2007087548  (SMITHKLINE BEECHAM CORP [US], et al) [A] 1-15 * abstract * * page 1, paragraph 1 * * page 11, paragraph 1 - paragraph 2 * * example - * * claim - * * claim 40 *;
 [A]WO2012049277  (PROXIMAGEN LTD [GB], et al) [A] 1-15 * abstract * * page 1, paragraph 1 * * example - * * claim - * * claim 20 *;
 [A]US2012141471  (SALVINO JOSEPH M [US], et al) [A] 1-15 * abstract * * paragraphs [0003] , [0011] * * example - * * claim - ** claim 6 *
International search[A]US7592351  (SUNDERMANN BERND [DE], et al) [A] 1* entire document *;
 [A]US2011206607  (OLSSON ROGER [SE], et al) [A] 1 * entire document *;
 [A]WO2015200341  (REDDYS LAB LTD DR [IN], et al) [A] 1 * entire document *;
 [A]  - PUBCHEM, (20141021), Database accession no. 219642471, XP055449556 [A] 1 * entire document *
by applicantFR901228
 WO0142246
 WO02088112
 US6552065
 WO03063794
 WO2004019973
 WO2004089925
 WO2004106328
 WO2005007623
 WO2005113554
 WO2006078846
 WO2006122806
 WO2007016176
 WO2007044729
 WO2007053452
 WO2007070514
 WO2007084786
 WO2007129161
 WO2008039218
 US7390799
 WO2008109943
 WO2008118802
 WO2009114512
 WO2011090760
 US8138347
 US8906682
    - VANHARANTA et al., Nat Med, (20130000), vol. 19, pages 50 - 56
    - GALEMCCOLL, BioEssays, (19990000), vol. 21, pages 17 - 28
    - HIGHFILL et al., Sci Transl Med, (20140000), vol. 6, page ra67
    - FACCIABENE et al., Nature, (20110000), vol. 475, pages 226 - 230
    - S. M. BERGE et al., pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, (19770000), vol. 66, pages 1 - 19
    - MCDERMOTT et al., Blood, (20100000), vol. 116, pages 2793 - 2802
    - MACIEJWESKI-DUVAL et al., J. Leukoc. Biol., (20150000), pages 5MA0815 - 288R
    - CONNOLLY et al., Int'l J. Biological Sciences, (20120000), vol. 8, pages 964 - 978
    - OKAZAKI, T. et al., Nat. Immunol., (20130000), vol. 14, pages 1212 - 1218
    - ZOU et al., Sci. Transl. Med., (20160000), vol. 8
    - "Principles of Radiation Therapy, Cancer", Principles and Practice of Oncology, Hellman, (19930000), vol. 1, pages 248 - 275
    - HOUBEN-WEYL, Methods of Organic Synthesis, Thieme, (19520000), vol. 21
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.